Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Number of DPC Hospitals to Increase to 718 in FY2008
March 10, 2008
- PMDA Announces Draft Operation and System Optimization Plan
March 10, 2008
- Range of Public Healthcare Benefits to Become Center of Discussions
March 10, 2008
- REGULATORY NEWS IN BRIEF
March 10, 2008
- Takashi Kodama Elected JPA President
March 10, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
March 10, 2008
- Ethical Drugs Market Exceeds \8 Trillion in 2007: IMS
March 10, 2008
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Daiichi Sankyo Places Top Priority on 5 Projects
March 3, 2008
- Sanofi-aventis Enters into Antibody Agreements with Dyax
March 3, 2008
- Blood Pressure Management Not Adequate: Pfizer Survey
March 3, 2008
- Toyobo Expands Contract Manufacturing Business
March 3, 2008
- NCCHD-Led NW to Participate in Multinational Clinical Trials
March 3, 2008
- Sales of Plavix Up 5.5-Fold in Japan: sanofi-aventis
March 3, 2008
- Development Delayed for 16 Unapproved Drugs
March 3, 2008
- Competition Heats Up on the Market for Statins
March 3, 2008
- Introduce GCP Auditor Certification System: Prof. Horie
March 3, 2008
- Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
March 3, 2008
- Korosho to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells
March 3, 2008
- Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
March 3, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…